Cubist Pharmaceuticals is a bio-pharmaceutical company focused on the research, commercial­ization and creation of pharmaceutical products that address unmet medical needs in the acute care environment.

Product Pipeline

Ceftolozane/tazobactam

Gram-negative CXA-201

for cUTI (complicated urinary tract infection) and
cIAI (complicated intra-abdominal infection)

Ceftolozane/tazobactam, which is being developed as a first-line intravenous therapy for the treatment of certain serious Gram-negative bacterial infections, including those caused by multi-drug resistant Pseudomonas aeruginosa, advanced into Phase 3 trials in July 2011…

Dificid

News & Press

13 Jun

Cubist Names Dr. Lorianne Masuoka Chief Medical Officer

Lexington, Mass., June 13, 2013 – Cubist Pharmaceuticals, Inc. (NASDAQ: CBST) today announced the appointment of Dr. Lorianne Masuoka to Chief Medical Officer and Senior Vice President, Clinical Development and Medical Affairs.

Careers at Cubist

Keith

Meet Keith

CBM, Birmingham West Region

A Clinical Business Manager in the Birmingham West region, Keith sees himself as one of the “faces of Cubist” with the…

Investor Center

Cubist Pharmaceuticals $51.13 +1.16
CBST (NASDAQ) UPD: 4:00pm